https://mb.cision.com/Public/18595/3877036/bbe6d7acff578d00_800x800ar.png
** =E2=80=98Rheumacensus=E2=80=99 experts unite and call for essential psor=
iatic arthritis and axial spondyloarthritis care improvements
------------------------------------------------------------
=C2=B7 UCB is sponsoring an expert-led, pan-European multistakeholder progr=
amme called Rheumacensus=C2=A0
=C2=B7 The programme brings together a variety of stakeholders to identify =
and propose solutions for key unmet care needs in two prevalent rheumatic c=
onditions=C2=A0
=C2=B7 The programme=E2=80=99s mission is to rethink standards of care in p=
soriatic arthritis and axial spondyloarthritis across Europe, driving chang=
e that makes a real difference to patients
Brussels (Belgium), 16 November 2023 =E2=80=93 7:00 am (CEST) =E2=80=93 As =
part of its longstanding commitment to patients in rheumatology, UCB, a glo=
bal biopharmaceutical company, is sponsoring an expert-led, multi-stakehold=
er programme called Rheumacensus. The programme aims to identify key challe=
nges in the current care pathways of psoriatic arthritis (PsA) and axial sp=
ondyloarthritis (axSpA) across Europe, and reach consensus on potential imp=
rovements.=C2=A0
Driven by 22 European experts, Rheumacensus combines healthcare professiona=
l (eight), patient (seven), and payor (seven) perspectives to ensure that e=
very aspect of managing PsA and axSpA is considered. Through a series of De=
lphi surveys, care gaps and unmet needs were defined, and consensus was sou=
ght on how the priority challenges should be addressed. Consensus council m=
eetings have been held to generate =E2=80=98calls to action=E2=80=99 which,=
if implemented consistently across Europe, could improve the standard of c=
are for people living with PsA and axSpA.
Of the programme, Paul Atherfold, European Advocacy and Medical Education L=
ead for Rheumatology and Dermatology at UCB said, =E2=80=9CDespite the prog=
ress made in recent years, severe unmet needs persist for those impacted by=
psoriatic arthritis and axial spondyloarthritis. Rheumacensus allows us to=
build our expertise with patients at the forefront of our thinking and cem=
ent our partnerships within the scientific community who are working hard t=
o address these unmet needs. Our ultimate goal is to elevate care for these=
patients, allowing them to live the lives they wish, as free as possible f=
rom challenges and uncertainty related to their condition.=E2=80=9D
Xenofon Baraliakos, Professor of Internal Medicine and Rheumatology at Ruhr=
-University Bochum, President of ASAS, Treasurer of EULAR, and member of th=
e Consensus Council for Rheumacensus, commented, =E2=80=9CThe unique appeal=
of this innovative programme is that it brings together perspectives from =
a variety of stakeholders from across Europe: patients, patient organisatio=
n representatives, payors, dermatologists, rheumatologists, nurses, and phy=
siotherapists. This approach allows us to take a 360-degree view of the cha=
llenges in front of us, learn from each other and propose practical solutio=
ns that will make a real difference for people living with axSpA and PsA.=
=E2=80=9D
=C2=A0
About Psoriatic Arthritis
Psoriatic arthritis (PsA) is a serious, highly heterogeneous, chronic, syst=
emic inflammatory condition affecting both the joints and skin, with a prev=
alence of 0.02 percent to 0.25 percent of the population, and 6 percent to =
41 percent of patients with psoriasis.^1 Symptoms include joint pain and st=
iffness, skin plaques, swollen toes and fingers (dactylitis) and inflammati=
on of the sites where tendons or ligaments insert into the bone (enthesitis=
) and/or spondylitis (pain, swelling, tenderness, stiffness).^2
About Axial Spondyloarthritis
Axial spondyloarthritis (axSpA), which includes both non-radiographic axSpA=
(nr-axSpA) and radiographic axSpA (r-axSpA), also known as ankylosing spon=
dylitis (AS), is a chronic, immune-mediated, inflammatory disease.3 nr-axSp=
A is defined clinically by the absence of definitive X-ray evidence of stru=
ctural damage to the sacroiliac joints.3 axSpA is a painful condition that =
primarily affects the spine and the joints linking the pelvis and lower spi=
ne (sacroiliac joints).^3 The leading symptom of axSpA in a majority of pat=
ients is inflammatory back pain lasting longer than 3 months that improves =
with exercise, but not with rest.^3,4 Other common clinical features freque=
ntly include anterior uveitis, enthesitis, peripheral arthritis, psoriasis,=
inflammatory bowel disease and dactylitis.^3 The overall prevalence of axS=
pA is 0.3 percent to 1.4 percent of adults.4 Approximately half of all pati=
ents with axSpA are patients with nr-axSpA.^3 axSpA onset usually occurs be=
fore the age of 45.^5 Approximately 10 to 40 percent of patients with nr-ax=
SpA progress to AS over 2 to 10 years.^3
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8,600 peopl=
e in approximately 40 countries, the company generated revenue of =E2=82=AC=
5.5 billion in 2022. UCB is listed on Euronext Brussels (symbol: UCB). Foll=
ow us on Twitter: @UCB_news.
For further information, contact UCB:=C2=A0
Global Communications
Adriaan Snauwaert
Tel: +32 497 70 23 46
Email: adriaan.snauwaert@ucb.com
Media Relations
Laurent Schots
Tel: +32 2 559 9264
Email: laurent.schots@ucb.com =C2=A0
Forward looking statements
This press release may contain forward-looking statements including, withou=
t limitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, =
=E2=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends=
=E2=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestim=
ates=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccont=
inue=E2=80=9D and similar expressions. These forward-looking statements are=
based on current plans, estimates and beliefs of management. All statement=
s, other than statements of historical facts, are statements that could be =
deemed forward-looking statements, including estimates of revenues, operati=
ng margins, capital expenditures, cash, other financial information, expect=
ed legal, arbitration, political, regulatory or clinical results or practic=
es and other such estimates and results. By their nature, such forward-look=
ing statements are not guarantees of future performance and are subject to =
known and unknown risks, uncertainties and assumptions which might cause th=
e actual results, financial condition, performance or achievements of UCB, =
or industry results, to differ materially from those that may be expressed =
or implied by such forward-looking statements contained in this press relea=
se. Important factors that could result in such differences include: change=
s in general economic, business and competitive conditions, the inability t=
o obtain necessary regulatory approvals or to obtain them on acceptable ter=
ms or within expected timing, costs associated with research and developmen=
t, changes in the prospects for products in the pipeline or under developme=
nt by UCB, effects of future judicial decisions or governmental investigati=
ons, safety, quality, data integrity or manufacturing issues; potential or =
actual data security and data privacy breaches, or disruptions of our infor=
mation technology systems, product liability claims, challenges to patent p=
rotection for products or product candidates, competition from other produc=
ts including biosimilars, changes in laws or regulations, exchange rate flu=
ctuations, changes or uncertainties in tax laws or the administration of su=
ch laws, and hiring and retention of its employees. There is no guarantee t=
hat new product candidates will be discovered or identified in the pipeline=
, will progress to product approval or that new indications for existing pr=
oducts will be developed and approved. Movement from concept to commercial =
product is uncertain; preclinical results do not guarantee safety and effic=
acy of product candidates in humans. So far, the complexity of the human bo=
dy cannot be reproduced in computer models, cell culture systems or animal =
models. The length of the timing to complete clinical trials and to get reg=
ulatory approval for product marketing has varied in the past and UCB expec=
ts similar unpredictability going forward. Products or potential products, =
which are the subject of partnerships, joint ventures or licensing collabor=
ations may be subject to differences disputes between the partners or may p=
rove to be not as safe, effective or commercially successful as UCB may hav=
e believed at the start of such partnership. UCB=E2=80=99s efforts to acqui=
re other products or companies and to integrate the operations of such acqu=
ired companies may not be as successful as UCB may have believed at the mom=
ent of acquisition. Also, UCB or others could discover safety, side effects=
or manufacturing problems with its products and/or devices after they are =
marketed. The discovery of significant problems with a product similar to o=
ne of UCB=E2=80=99s products that implicate an entire class of products may=
have a material adverse effect on sales of the entire class of affected pr=
oducts. Moreover, sales may be impacted by international and domestic trend=
s toward managed care and health care cost containment, including pricing p=
ressure, political and public scrutiny, customer and prescriber patterns or=
practices, and the reimbursement policies imposed by third-party payers as=
well as legislation affecting biopharmaceutical pricing and reimbursement =
activities and outcomes. Finally, a breakdown, cyberattack or information s=
ecurity breach could compromise the confidentiality, integrity and availabi=
lity of UCB=E2=80=99s data and systems.=C2=A0
Given these uncertainties, you should not place undue reliance on any of su=
ch forward-looking statements. There can be no guarantee that the investiga=
tional or approved products described in this press release will be submitt=
ed or approved for sale or for any additional indications or labelling in a=
ny market, or at any particular time, nor can there be any guarantee that s=
uch products will be or will continue to be commercially successful in the =
future.
UCB is providing this information, including forward-looking statements, on=
ly as of the date of this press release. UCB expressly disclaims any duty t=
o update any information contained in this press release, either to confirm=
the actual results or to report or reflect any change in its forward-looki=
ng statements with regard thereto or any change in events, conditions or ci=
rcumstances on which any such statement is based, unless such statement is =
required pursuant to applicable laws and regulations.=C2=A0
Additionally, information contained in this document shall not constitute a=
n offer to sell or the solicitation of an offer to buy any securities, nor =
shall there be any offer, solicitation or sale of securities in any jurisdi=
ction in which such offer, solicitation or sale would be unlawful prior to =
the registration or qualification under the securities laws of such jurisdi=
ction.=C2=A0
References
1. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Cli=
n North Am. 2015;41(4):545=E2=80=9368.=C2=A0
2. Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the di=
agnosis and pharmacologic treatment of psoriatic arthritis in patients with=
psoriasis. Drugs. 2014;74(4):423=E2=80=9341.
3. Deodhar A. Understanding axial spondyloarthritis: A primer for managed c=
are. Am J Manag Care. 2019;25:S319=E2=80=9330.
4. Axial Spondyloarthritis International Federation. About ASIF. https://as=
if.info/about/. Last accessed August 2023.
5. Boel A, L=C3=B3pez-Medina C, van der Heijde DMFM, van Gaalen FA. Age at =
onset in axial spondyloarthritis around the world: data from the Assessment=
in SpondyloArthritis international Society Peripheral Involvement in Spond=
yloarthritis study. Rheumatology (Oxford). 2022;61(4):1468=E2=80=9375.
GenericFile
Rheumacensus press release FINAL (https://mb.cision.com/Public/18595/387703=
6/a71ac41bbe14453c.pdf)
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x148760x1x6868579x2400=
0x6&Email=3Dregnews%40symexglobal.com.
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
26/04/2024 20:00
25/04/2024 18:00
25/04/2024 07:01
23/04/2024 20:00
22/04/2024 07:01
19/04/2024 20:00
17/04/2024 07:01
12/04/2024 20:00
12/04/2024 18:01
12/04/2024 07:01